Company Profile

PafosPharma LLC
Profile last edited on: 5/28/21      CAGE: 777K8      UEI: RAMVJ5PCTRJ5

Business Identifier: Novel medications for therapeutic indications related to endocannabinoid biochemical system
Year Founded
2017
First Award
2019
Latest Award
2019
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

151 South Bedford Street Mail Box #3
Burlington, MA 01803
   (781) 365-0958
   c.clayton@pafospharma.com
   www.pafospharma.com
Location: Single
Congr. District: 06
County: Middlesex

Public Profile

PafosPharma, LLC, a privately held biopharmacetical company is dedicated to developing novel medications for therapeutic indications related to the endocannabinoid biochemical system. Located in Burlington, MA, Pafos is based on 35 years of cannabinoid research by Professor Alexandros Makriyannis - George D. Behrakis Endowed Chair, Director of the Center for Drug Discovery, Northeastern University. PafosPharma has substantial drug development assets that include (i) proprietary understanding of all the major endocannabinoid pathway(s), (ii) validated targets for therapeutic drug development, and (iii) a library of potent and highly selective cannabinergic compounds some of which are currently in preclinical testing. The Company owns various families of pharmacologically active compounds being utilized as targets for drug discovery for conditinsranging from Irritable Bowel Syndrome, through addiction, PTSD and Neuropathic Pain.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2019 1 NIH $225,000
Project Title: Medications for Synthetic Cannabinoid Abuse

Key People / Management

  Alexandros Makriyannis -- Founder

  Caroline Clayton

Company News

There are no news available.